杉杉来了

雅迪控股 2026 财年半年报归母净利润 12.01 亿元，同比下降 27.2%_我的网站

A |      8 月 25 日消息，雅迪控股今日发布 2026 财年（2026 年 1 月～2026 年 12 月）半年报（2026 年 1 月～2026 年 6 月）报告：营业总收入：182.36 亿元，同比下降 5% 毛利润：32.36 亿元，同比下降 14% 毛利率：17.7% 归母净利润：12.01 亿元，同比下降 27.2% 经营现金流：16.26 亿元，同比下降 65.6% 基本每股收益：0.394 元，同比下降 27.4% 稀释每股收益：0.394 元，同比下降 27.4% 资产负债率：10.4% AI 解读 本次 2026 财年上半年业绩低于市场平均预期，收入、归母净利润均同比下滑，处于行业新国标过渡期调整阶段。    Shares of Pfizer are in retreat on the first day of trading after the drug company said sales of its COVID-19 vaccine and its coronavirus treatment are weaker than it had expected and cut revenue projections by $9 billion for the year. Falling sales of both clipped sales in the second quarter, but Pfizer said in August that it expected a rebound in the second half of 2023. Shares of Pfizer slipped more than 1% before the opening bell Monday and Moderna, which is heavily reliant on the competing vaccine it makes, slid nearly 5%. Pfizer said Friday that global usage of Paxlovid is trending slightly above last year, but that it's still below expectations.The fall vaccination period just began and the New York City drugmaker said that it's too soon to get a handle on vaccination rates for the year.Full-year revenue for Paxlovid and Comirnaty is expected to be approximately $12.5 billion, short $9 billion of what it had expected. Pfizer is lowering its full-year revenue expectations for Paxlovid by approximately $7 billion. That number also accounts for delayed commercialization of the product, which was pushed to January 2024 from the company's previous expectation of commercialization in the second half of this year. Pfizer is also lowering its 2023 revenue expectations for Comirnaty by approximately $2 billion due to lower-than-expected vaccination rates.Pfizer Inc. now foresees 2023 revenue in a range of $58 billion to $61 billion, down from its prior forecast for $67 billion to $70 billion. It now projects full-year adjusted earnings between $1.45 and $1.65 per share due to lower-than-anticipated revenue for COVID-19-related products and inventory write-offs.That is short of the full-year revenue of $63.61 billion and earnings of $2.77 per share that Wall Street was expecting, and far short of the company's previous projections of per-share earning between $3.25 and $3.45. JPMorgan said the company's update solves an ongoing U.S. Paxlovid inventory debate and it anticipates the company's bigger-than-expected cuts to its sales projections will help put a floor under per-share earnings expectations for next year.。财报核心亮点营业收入：1.82 万亿元 ，同比 -5%，主要受电动自行车、电池及充电器销量下降影响；电动自行车销量同比减少约 37.8%，电动踏板车销量同比增长约 63.7%，消费需求转向电动踏板车趋势明显。毛利润：3235.9 亿元 ，同比 -14%；毛利率降至 17.7% ，同比下降 1.9 个百分点，主要受产品结构变化及电池分部毛利率下降影响。归属于母公司股东净利润：1200.9 亿元 ，同比 -27.2%；基本每股收益 0.39 元 ，同比 -27.4%。海外业务保持强劲增长，东南亚等市场需求提升，公司通过越南新生产基地强化本地化能力，支撑海外长期增长。资产负债率降至 10.4%，较上年末下降 7.0 个百分点，整体偿债能力优化。

B | 未来展望公司预计 2026 年下半年国内市场逐步适应新国标，需求逐步恢复；将持续推进产品创新、优化产品组合、提升运营效率，深化海外市场布局，强化本地化供应能力，巩固竞争优势，支撑长期可持续增长。相关阅读：风险提示：本文内容由 AI 自动分析生成，仅供参考，不代表观点。如有出入请以证监会指定上市公司信息披露平台为准。本文内容不构成投资建议，如有投资者据此操作，风险自担，对此不承担任何责任。

Current article:http://www.linlangdouwaqiexusan.bond/znm/97t.html

Published on:07:24:19